Vimta Labs
- Market cap
- ₹ 2,092 Cr.
- P/E
- 34.5x
- P/B
- 4.79x
- 52-week range
- 376.05 – 735
- ROE
- 19%
- ROCE
- 25%
- Dividend yield
- 0.4%
- Debt / equity
- 0.01
- Sector
- Healthcare Services
- Industry
- Healthcare Research, Analytics & Technology
- Listed on
- NSE, BSE
About
Vimta Labs Limited is an India-based contract research and testing services provider. The Company operates through the Contract Research and Testing Services segment. It is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ore and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include drug discovery, development, and drug life cycle management support services; preclinical research and testing services for medical device companies; contract research and testing for agrochemical and specialty chemical companies; food testing and analytical development services to support manufacturers, processors, farmers, and retailers; contact research and development of biologics and peptides and electrical/electronic safety, environmental and physical security products testing.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Research, Analytics & Technology: 11 companies →Vimta Labs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)34.5 against a typical 34.2: pricier than most peers (1st = cheapest).7th of 11
- Sales growth+11.2% against a typical +16.4% from a year earlier.6th of 10
- Profit growth+10.5% against a typical 0% from a year earlier.2nd of 5
- Share price, 3 months−14.7% against a typical −13%.7th of 11
- Size₹ 2,091.9 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).4th of 11
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A | Stable | 2 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 2 Sep 2026 | Reaffirmed | CARE A | — | CARE | ₹ 61.28 Cr. | |
| 6 Aug 2025 | Reaffirmed | CARE A | — | CARE | ₹ 73.45 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 20 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 6 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 28 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 3 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 17 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 along with other items of agenda |
| 14 Jun 2025 | Board meeting Rescheduled | Vimta Labs Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled to be held on Jun 14, 2025 To consider and approve allotment of Bonus Equity Shares. has been cancelled as the Board will consider the said agenda through circulation. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 64 | 73 | 73 | 75 | 85 | 90 | 94 | 98 | 102 | 99 | 109 | 109 |
| Expenses | 48 | 50 | 47 | 49 | 55 | 57 | 61 | 64 | 68 | 64 | 70 | 72 |
| Operating Profit | 17 | 23 | 26 | 26 | 30 | 33 | 33 | 34 | 34 | 34 | 39 | 37 |
| OPM % | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% | 34% | 35% | 36% | 34% |
| Other Income | 0 | −1 | −1 | −1 | −1 | 5 | 2 | 2 | 3 | 0 | 3 | 4 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 | 10 | 11 | 13 | 13 |
| Profit before tax | 8 | 13 | 16 | 17 | 20 | 28 | 25 | 25 | 26 | 23 | 29 | 28 |
| Tax % | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% | 24% | 25% | 27% | 26% |
| Net Profit | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 | 20 | 18 | 21 | 21 |
| EPS in Rs | 1.34 | 2.14 | 2.79 | 2.77 | 3.44 | 4.84 | 4.12 | 4.24 | 4.47 | 3.94 | 4.73 | 4.71 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 11%
- 5 Years
- 14%
- 3 Years
- 9%
- TTM
- 14%
- 10 Years
- 29%
- 5 Years
- 30%
- 3 Years
- 19%
- TTM
- 13%
- 10 Years
- 30%
- 5 Years
- 34%
- 3 Years
- 29%
- TTM
- —
- 10 Years
- 15%
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vimta Labs | ₹ 510.00 | ₹ 2,092 Cr. | 34.5x | 4.8x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sivalinga Prasad Vasireddi
- Executive Chairman of the Board
- Siva Rama Krishna Kambhampati
- Chief Financial Officer
- Sujani Vasireddi
- Company Secretary, Compliance officer
- Harita Vasireddi
- Managing Director, Executive Director
- Satya Sreenivas Neerukonda
- Executive Director
- Harriman Vungal
- Executive Director - Operations
Prices are delayed and for information only. Nothing on this page is investment advice.